Article

Rising Legislative Scrutiny of PBMs Highlights AJPB Week in Review

Author(s):

Davy James, Managing Editor

Top stories of the week on The American Journal of Pharmacy Benefits.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Creative layout of colorful pills and capsules on blue background. Minimal medical concept. Pharmaceutical, Covid-19 or Coronavirus. Flat lay, top view
June 26th 2025

Mid-Year Roundup: FDA’s Novel Retail and Specialty Drug Approvals in 2025

Luke Halpern, Assistant Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Pediatric multisystem inflammatory syndrome. kawasaki disease symptoms.
June 23rd 2025

IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C

Luke Halpern, Assistant Editor
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid
June 20th 2025

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

Aislinn Antrim, Managing Editor